hoodb.com

安成生技(6610)公告用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203,獲得西班牙AEMPS同意進行第二/三期人體臨床試驗(1/8日股價13.8元)

|

You are leaving and open the following URL" of about "-巴黎奧運 8" news

news.google.com/rss/articles/CBMickFVX3lxTE5xZ09iaDlzTlBEU1dpa2FFbHdMVUowcEZ5bVM5bUplT0ZtbW1WWVhmWHhyN1ZSR2Z5Yk9BbmlCbkN0bWdkWHFKMnJacXNUN3pQS2RnVnV4b0c0Vm9hdkx2RU4tTGJxemJEZk10bkh6V0JNdw?oc=5


Continue Opne >

-巴黎奧運 8: 安成生技(6610)公告用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203,獲得西班牙AEMPS同意進行第二/三期人體臨床試驗(1/8日股價13.8元)


More -巴黎奧運 8 news:



Warning: filemtime(): stat failed for aCache/aaa/gnews/RO/-巴黎奧運 8.xml in /var/www/hoodb/function.php on line 339
1736456699-
Warning: file_put_contents(aCache/aaa/gnews/RO//-巴黎奧運 8.xml): Failed to open stream: No space left on device in /var/www/hoodb/function.php on line 348

About -巴黎奧運 8

from
1736456700-1736280979

Warning: filemtime(): stat failed for aCache/search/ro/-巴黎奧運 8 in /var/www/hoodb/function.php on line 339
1736456700-

-巴黎奧運 8, 安成生技(6610)公告用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203,獲得西班牙AEMPS同意進行第二/三期人體臨床試驗(1/8日股價13.8元) 2022 -巴黎奧運 8

安成生技(6610)公告用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203,獲得西班牙AEMPS同意進行第二/三期人體臨床試驗(1/8日股價13.8元)

Choose Your Country or Region


Back to Top



安成生技(6610)公告用於治療單純型遺傳性表皮分解性水皰症(EBS)之開發中新藥AC-203,獲得西班牙AEMPS同意進行第二/三期人體臨床試驗(1/8日股價13.8元)

Copyright © 2020-2021 hoodb.com. All Rights Reserved.